Navigation Links
Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival
Date:10/25/2011

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from a Bayer HealthCare Pharmaceuticals Phase 3 trial evaluating the investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies. The trial met its primary endpoint of statistically significant improvement in overall survival. This is the result of a pre-planned interim analysis conducted by an independent Data Monitoring Committee (DMC) of the CORRECT (Patients with metastatic colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial. Per the recommendation of the DMC, the study has been unblinded and patients in the placebo arm will be offered treatment with regorafenib. In this trial, the safety and tolerability of regorafenib were generally as expected.  Data from the study are expected to be presented at a forthcoming scientific meeting.

Onyx recently entered into an agreement with Bayer under which Bayer will pay Onyx a royalty on any future global net sales of regorafenib in oncology.

"Patients with metastatic colorectal cancer are in need of new treatment options, and these data demonstrate that regorafenib increased overall survival," said Ted W. Love, M.D., Executive Vice President, Research and Development and Technical Operations at Onyx Pharmaceuticals. "We look forward to seeing this promising therapy become available to patients as quickly as possible."

Bayer will continue discussions with health authorities worldwide, including the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA), regarding next steps in filing for approval of regorafenib in the treatment of mCRC.

About the CO
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF)
2. Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases
3. Data From Phase 2 Clinical Studies of Telotristat Etiprate in Patients With Carcinoid Syndrome to be Presented at North American Neuroendocrine Tumor Society Meeting
4. DIFICID™ Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
5. First Results From Ongoing Phase III Trial Show Malaria Vaccine Candidate, RTS,S* Reduces the Risk of Malaria by Half in African Children Aged 5 to 17 Months
6. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
7. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
8. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
9. Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
10. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
11. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... LAUDERDALE, Fla. , July 2, 2015 /PRNewswire/ ... Co., is pleased to announce that its Consumer ... ("Insight Beverages") to Kerry Group plc (ISE: KRZ) ... on taste and nutrition systems, as well as ... beverage and pharmaceutical markets. Farlie Turner served as ...
(Date:7/2/2015)... , July 2, 2015 Roche,s ... conspicuously high-growth market segment in hematology testing, according ... said that Roche,s recent unveiling of its Bloodhound digital ... cobas m 511 hematology analyzer – ... capture growth enjoyed by current leader CellaVision, but ...
(Date:7/2/2015)... , June 25, 2015 Research ... "Cancer Diagnostics Market by Technology, Imaging and by Application - Forecast ... cancer diagnostics market is expected to reach $13.1 Billion in 2020 ... of 12.9%. The market is dominated by ... Asia , and Rest of the World (RoW). ...
Breaking Medicine Technology:Farlie Turner's Consumer Group Completes Sale of Insight Beverages to Kerry 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3Global Cancer Diagnostics Market Report 2015 - Technology, Imaging and by Applications Forecasts to 2020 for the $13 Billion Industry 2
(Date:7/3/2015)... Greenville, SC (PRWEB) , ... ... ... Society has announced the sessions and speaker lineup for its 2015 ... nursing, taking place August 6-8, 2015 at the Renaissance Orlando at SeaWorld ...
(Date:7/3/2015)... ... July 03, 2015 , ... The Erie County Bar ... at 1:00pm. The Association welcomed speaker C. Daniel McGillicuddy Esq. of William Mattar ... points of investigating these types of cases. , Each year, New York State ...
(Date:7/3/2015)... ... July 03, 2015 , ... " Selfie on a Stick ” was ... and coolest technology products available to consumers. Amanda Forstrom, a technology expert and special ... are great for documenting memories. , Almost every smartphone has an incredibly powerful camera ...
(Date:7/2/2015)... ... ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest location in Dallas, ... The premium frozen yogurt chain was listed as #22 on the Inc. 500 list of ... at Bachman Lake, is located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 ...
(Date:7/2/2015)... Lincoln, RI (PRWEB) , ... July 02, 2015 , ... ... keep safety in mind. That’s why Amica Insurance is sharing some tips ... Safety Commission (CPSC), approximately 230 people go to the emergency room daily with fireworks-related ...
Breaking Medicine News(10 mins):Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:6 Fireworks Safety Tips from Amica Insurance 2
... Northern Response begins taking orders for foreign ... Oct. 28 uKarma Corporation (OTC,Bulletin Board: ... company,focused on health, wellness and personal development, ... Response (International),Ltd, showcased uKarma,s innovative Xflowsion DVD ...
... programs expand URAC,s Pharmacy,Quality Management(SM) Initiative, ... four,companies have achieved accreditation for the new ... Management(SM) initiative., (Logo: http://www.newscom.com/cgi-bin/prnh/20030501/URACLOGO ... voluntary accreditation program of,this scope for the ...
... drugs -- statins -- appear to lower men,s PSA values ... Duke Prostate Center and the Durham Veterans Affairs Medical Center. ... just mask it is not known yet. , "Previous studies ... develop advanced forms of prostate cancer but no one had ...
... surveying patients in more than 1,500 physician practices ... health-care experiences, with minority patients having worse experiences ... all doctors should be attentive to differences in ... are often visiting physician practices that are less ...
... Applicator Now Available ... at Walgreens and Walgreens.com, MILWAUKEE, Oct. 28 ... today announced the arrival of new Carmex,Moisture Plus(TM) ultra-hydrating ... aloe, shea butter and avocado,butter. Available exclusively at Walgreens ...
... Animal Health,International, Inc. (Nasdaq: AHII ) announced ... fiscal year 2009 first quarter ended,September 30, 2008 on ... a conference call the same day at 10:00 a.m.,Eastern ... outlook., You can access the conference call by ...
Cached Medicine News:Health News:uKarma Reports Progress With International Distribution Agreement for Its Xflowsion DVD Series 2Health News:Four Companies Are First to Achieve Accreditation Under Two New URAC Pharmacy Quality Management(SM) Programs 2Health News:Cholesterol-lowering drugs may also lower PSA, but whether they cut cancer risk is still not known 2Health News:Racial and ethnic disparities detected in patient experiences 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: